Screening for Reproductive Functional Decline Before Assisted Reproductive Treatment

Abstract

Reproductive functional decline is a critical consideration in the context of assisted reproductive treatment (ART). Effective screening prior to ART can identify underlying causes of reproductive inefficiency and inform individualized management plans, ultimately improving clinical outcomes. This review synthesizes current evidence regarding epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approaches, management strategies, recent advances, and guideline recommendations related to screening for reproductive functional decline before ART. Emphasis is placed on integrating recent research findings and clinical guidelines to provide a comprehensive, practical resource for clinicians involved in reproductive medicine.

Introduction

Assisted reproductive technologies have revolutionized fertility care, offering hope to individuals and couples facing infertility. However, the success of ART interventions is intimately linked to baseline reproductive function, which often declines due to a range of physiological and pathological processes. Screening for reproductive functional decline prior to initiating ART is an essential step in optimizing patient selection, tailoring interventions, and enhancing overall success rates. This article examines the multifactorial nature of reproductive functional decline, discusses the utility of various screening modalities, and provides evidence-based recommendations for clinical practice.

Epidemiology / Disease Burden

Infertility affects an estimated 8-12% of reproductive-aged couples globally. The prevalence of diminished ovarian reserve (DOR) and other forms of reproductive functional decline increases with maternal age, particularly after 35 years. Male reproductive functional decline, characterized by reduced semen quality and hormonal dysregulation, is also a significant contributor to infertility. ART utilization has risen steadily, with over 2.5 million cycles performed annually worldwide. However, suboptimal reproductive function remains a key limitation to ART success, highlighting the importance of early and accurate screening.

Pathophysiology

Reproductive functional decline is a complex, multifactorial process involving genetic, environmental, and lifestyle factors. In females, age-related depletion of ovarian follicles, mitochondrial dysfunction, and increased oxidative stress contribute to declining oocyte quality and quantity. Additional mechanisms include autoimmune oophoritis, chemotherapy-induced gonadotoxicity, and chronic medical illnesses such as endometriosis and polycystic ovary syndrome (PCOS). In males, pathophysiological changes encompass reduced spermatogenesis, hormonal imbalances (notably declines in testosterone and inhibin B), increased DNA fragmentation, and testicular microenvironment alterations.

Risk Factors

Key risk factors for reproductive functional decline include advanced age, family history of premature ovarian insufficiency, prior ovarian surgery, exposure to gonadotoxins (e.g., chemotherapy, radiotherapy), metabolic disorders (e.g., obesity, diabetes), smoking, excessive alcohol consumption, and environmental toxins. Male risk factors similarly include age, exposure to heat or toxins, varicocele, chronic systemic illness, and certain genetic abnormalities such as Y-chromosome microdeletions.

Clinical Features

Reproductive functional decline may present insidiously or with overt clinical manifestations. In females, signs include menstrual irregularities, oligomenorrhea, amenorrhea, or shortened menstrual cycles, often accompanied by vasomotor symptoms in advanced stages. In males, symptoms are typically non-specific but may include decreased libido, erectile dysfunction, or infertility as the presenting complaint. Subclinical decline is common, necessitating reliance on biochemical and functional screening tools for early detection.

Diagnosis

Diagnostic evaluation is anchored in a combination of detailed history, physical examination, and targeted laboratory testing. In females, ovarian reserve assessment via serum anti-Müllerian hormone (AMH) levels, basal follicle-stimulating hormone (FSH), estradiol concentrations, and antral follicle count (AFC) by transvaginal ultrasound are standard. Additional tests may include inhibin B and dynamic ovarian reserve assessments. For males, semen analysis remains the cornerstone, supplemented by hormonal profiling (FSH, LH, testosterone, prolactin), genetic testing, and advanced sperm function assays (e.g., DNA fragmentation index). Imaging modalities such as scrotal ultrasound may uncover structural abnormalities.

Treatment & Management

Management strategies are individualized and depend on the degree and etiology of functional decline. In females, pre-ART optimization may include lifestyle modification, antioxidant therapy, ovulation induction, or ovarian stimulation protocols tailored to ovarian reserve status. For males, interventions range from lifestyle changes and medical therapy (e.g., clomiphene, gonadotropins) to surgical correction of varicocele or sperm retrieval procedures. Early identification through screening enables timely referral to ART and consideration of adjuncts such as preimplantation genetic testing or oocyte/embryo cryopreservation.

Recent Advances / Emerging Therapies

Recent innovations in screening include the use of advanced biomarkers (e.g., granulosa cell-derived factors, microRNAs), machine learning algorithms for predictive modeling, and non-invasive imaging techniques. Emerging therapies under investigation encompass mitochondrial replacement techniques, stem cell-based approaches for ovarian rejuvenation, and novel pharmacological agents targeting specific pathways implicated in reproductive aging. Genetic screening for monogenic or polygenic causes of reproductive decline is gaining traction, particularly in personalized ART planning.

Guideline Recommendations

Professional societies such as the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) recommend routine pre-ART screening for reproductive functional decline. Guidelines advocate for age-appropriate ovarian reserve testing in all women considering ART, comprehensive semen analysis in men, and risk factor modification where feasible. Individualized counseling regarding prognosis, treatment options, and potential for oocyte or sperm donation is emphasized. Periodic updates to guidelines reflect evolving evidence and incorporate emerging diagnostic and therapeutic modalities.

Conclusion

Screening for reproductive functional decline prior to assisted reproductive treatment is integral to optimizing ART success and patient satisfaction. Timely identification of at-risk individuals facilitates targeted interventions, improves prognostic accuracy, and allows for informed decision-making. Ongoing research into novel biomarkers, predictive models, and regenerative therapies promises to further refine screening and management paradigms. Clinicians must remain abreast of guideline recommendations and advances in reproductive medicine to provide evidence-based, individualized care for patients seeking fertility treatment.